A5112371107- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Adenosine and Purinergic Signaling
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
Fudan University Shanghai Cancer Center
2024
Fudan University
2018
Zhongshan Hospital
2018
<b><i>Background:</i></b> Hepatocellular carcinoma (HCC) (about 85–90% of primary liver cancer) is particularly prevalent in China because the high prevalence chronic hepatitis B infection. HCC fourth most common malignancy and third leading cause tumor-related deaths China. It poses a significant threat to life health Chinese people. <b><i>Summary:</i></b> This guideline presents official recommendations National Health Family Planning...
<p>Supplementary materials and methods, Supplementary Figures figure legends, Tables</p>
<div>Abstract<p>Anti–PD-L1–based combination immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma (HCC). However, objective response rate is lower than 40%, highlighting need to identify mechanisms of tolerance immune checkpoint inhibitors and accurate biomarkers response. In this study, we used next-generation sequencing analyze HCC samples from 10 patients receiving anti–PD-L1 therapy. Activation renin–angiotensin system was elevated in...
Abstract Anti-PD-L1-based combination immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma (HCC). However, objective response rate is lower than 40%, highlighting need to identify mechanisms of tolerance immune checkpoint inhibitors and accurate biomarkers response. Here, we employed next-generation sequencing analyze HCC samples from 10 patients receiving anti-PD-L1 therapy. Activation renin-angiotensin system was elevated in nonresponders compared...